254. ポルフィリン症
[臨床試験数:59,薬物数:52(DrugBank:17),標的遺伝子数:17,標的パスウェイ数:33]
Searched query = "Porphyria", "CEP", "Erythropoietic protoporphyria", "EPP", "X-linked dominant protoporphyria", "XLDP", "PCT", "HEP", "AIP", "ADP", "VP", "Hereditary coproporphyria", "HCP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03118674 (ClinicalTrials.gov) | September 6, 2017 | 13/4/2017 | Harvoni Treatment Porphyria Cutanea Tarda | Newer Direct-Acting Anti-Viral Agents as Sole Therapy of Porphyria Cutanea Tarda in Subjects With Chronic Hepatitis C | Porphyria Cutanea Tarda;Hepatitis C | Drug: Harvoni | Wake Forest University Health Sciences | Gilead Sciences;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);National Institutes of Health (NIH) | Recruiting | 18 Years | N/A | All | 49 | Phase 2 | United States |